Skip to content

Allphase Pharma Consulting, LLC

A Professional Service Provider for the Pharma Industry

Allphase Pharma Consulting, LLC
Menu
Secondary Menu

Primary menu

  • CONTACT
  • BLOGS
    • The Viewpoint
    • The News
    • Recent Literature
    • Did you know…?
    • QIDP Antibiotics
  • LEGAL

Secondary menu

  • The News
  • The Viewpoint
  • Did you know…?
  • Recent Literature
  • QIDP Antibiotics

Tag Archives: cefaclor

Efficacy and Treatment Duration: Where is the Tipping Point?

Posted on March 14, 2017 by Harald — No Comments ↓

Development pf antibacterials differs in several important ways from drug development in other areas, and the lack of standard dose-finding is just one of them. Dose-finding in its most basic form involves ascending amounts of drug for efficacy and safety; Continue reading Efficacy and Treatment Duration: Where is the Tipping Point?→

Share this:

  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on Google+ (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email this to a friend (Opens in new window)

Like this:

Like Loading...
Posted in Recent Literature, The Viewpoint | Tagged acute otitis media, amoxicillin-clavulanate, amoxiclav, antibiotic blog, AOM, Avelox, cefaclor, Cefditoren, cIAI, Cipro, ciprofloxacin, complicated intra-abdominal infection, cystitis, duration response relationship, efficacy - duration of therapy relationship, Harald Reinhart, moxifloxacin, PCT, penicillin, pharyngitis, PK/PD, procalcitonin test, Tipping Point for efficacy, TMP/SMX, tonsillitis, uncomplicated UTI, uUTI, VAP, ventilator-associated pneumonia | Leave a reply

Primary Sidebar Widget Area

Posts and Blogs

  • Connections: From Mima/Herellea to Acinetobacter to the Double Helix to Lwoff to … CRAB
  • The Weak Correlation Between Antibiotic Action and Mortality
  • FDA Needs Radical Reform
  • The Letermovir Top-Line Results are Out – Or Are They?
  • The CDC and Spectinomycin
  • GC Therapy –  Shooting for the Stars
  • Efficacy and Treatment Duration: Where is the Tipping Point?
  • QIDP, a Liberal Hand-Out from FDA
  • CMV Connections: Paul-Bunnell Negative Mononucleosis and ‘Changelings’
  • Google Search for News on “Antibiotics”

Subscribe to AllphasePharma Blogs via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

View Author Site on LinkedIn

View Harald Reinhart's profile on LinkedIn

Tags

ABSSSI Allphase Pharma Consulting aminoglycoside antibiotic blog Avelox Bayer Ceftazidime/avibactam cIAI ciprofloxacin colistin Cubicin Cubist cUTI dalbavancin Dalvance daptomycin delafloxacin eravacycline FDA FDA Guidance fosfomycin GSK Harald Reinhart levofloxacin Merck meropenem moxifloxacin MRSA Novartis omadacycline Orbactiv oritavancin P. aeruginosa Pfizer PK/PD plazomicin QIDP solithromycin tedizolid tetracycline Tetraphase tigecycline Tygacil vancomycin VAP

How do you feel about the recent proliferation of Guidelines? (you may check more than option):

View Results

Loading ... Loading ...

Footer menu

  • CONTACT
  • BLOGS
  • LEGAL
  • Email
Copyright © 2019 Allphase Pharma Consulting, LLC. All Rights Reserved.
Theme: Catch Box by Catch Themes
Scroll Up
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
%d bloggers like this: